In this regard, we designed and produced a novel generation of tri-specific tribodies that not only can bind to 5T4 antigen on tumor cells and TCR/CD3 complex on the cytotoxic T cells to activate T cells bypassing TCR/MHC recognition, but they could also be resistant to cancer immunosuppressive environment. Here, HLA-C is linked to neoplasm.